Sign inJoin waitlistJoin the waitlist

Joseph Attallah

Associate Professor, Department of Medicine · Case Western Reserve University, School of Medicine

Credentials: · · · · · · ·

History

Case Western Reserve University, School of Medicine
Present
Case Western Reserve University, School of Medicine
Present
Case Comprehensive Cancer Center
Present

Hematology and Medical Oncology
Henry Ford St. John Hospital
2026–Present
Ascension St. John Hospital
2022–2025
ASYUT UNIV FAC OF MEDCINE , ASYUT
2018–2022

Research

Obese communities among the best predictors of COVID-19-related deaths
Cardiovascular Endocrinology & Metabolism · 2020 · 17 citations
Oxaliplatin Antibody-Related Thrombocytopenia: A Case Report
Case report · Cureus · 2024 · 2 citations
Executive summary of American Radium Society Appropriate Use Criteria for the treatment of locoregionally recurrent rectal cancer
Systematic review or meta-analysis · Cancer · 2026

Chris Hallemeier
5 papers
Christopher Anker
5 papers
Diane Ling
5 papers
Dmitriy Akselrod
5 papers
Gerard Abood
5 papers
Krishan Jethwa
5 papers
Leila Tchelebi
5 papers
Navesh Sharma
5 papers
Neil Newman
5 papers
Percy Lee
5 papers
Timothy Kennedy
5 papers
William Small
5 papers

Clinical trials

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2026–2034
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Site PI · Recruiting · Phase 3
Canadian Cancer Trials Group
2025–2031
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Site PI · Recruiting · Phase 2
Alliance for Clinical Trials in Oncology
2025–2034
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2023–2032